KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders: 2012-2025

Historic Net Income towards Common Stockholders for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$451.8 million.

  • Sarepta Therapeutics' Net Income towards Common Stockholders fell 6744.28% to -$451.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$252.2 million, marking a year-over-year decrease of 626.07%. This contributed to the annual value of $235.0 million for FY2024, which is 143.83% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Net Income towards Common Stockholders of -$451.8 million as of Q2 2025, which was down 384.52% from $158.8 million recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year Net Income towards Common Stockholders high stood at $158.8 million for Q4 2024, and its period low was -$516.8 million during Q1 2023.
  • In the last 3 years, Sarepta Therapeutics' Net Income towards Common Stockholders had a median value of $6.8 million in 2024 and averaged -$83.5 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Net Income towards Common Stockholders soared by 248.80% in 2024, and later plummeted by 6,744.28% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$122.0 million in 2021, then climbed by 9.94% to -$109.9 million in 2022, then soared by 141.44% to $45.5 million in 2023, then soared by 248.80% to $158.8 million in 2024, then crashed by 6,744.28% to -$451.8 million in 2025.
  • Its last three reported values are -$451.8 million in Q2 2025, $158.8 million for Q4 2024, and $34.0 million during Q3 2024.